At the recent San Antonio Breast Cancer Symposium (SABCS), Dr. Jiong Wu from Fudan University Shanghai Cancer Center and his team presented several significant research findings, offering new insights into breast cancer treatment.

The 47th San Antonio Breast Cancer Symposium (SABCS) was grandly held from December 10–13, 2024, in San Antonio, USA, showcasing significant global advancements in breast cancer research. During the conference, Dr. Xiaojia Wang from the Cancer Hospital of the University of the Chinese Academy of Sciences (Zhejiang Cancer Hospital) presented several important research findings. These included innovative treatment strategies with the new PD-1/VEGF bispecific antibody Ivosidenib and the novel antibody-drug conjugate (ADC) ARX788. Additionally, multiple real-world studies (RWS) provided valuable clinical insights into intensified adjuvant therapy for early-stage HER2-positive breast cancer, systemic therapy for advanced breast cancer, and breast cancer bone metastases. These contributions amplified the voice of China in breast cancer research at SABCS.Oncology Frontier interviewed Dr. Xiaojia Wang at the conference to share key data from these studies.

The de-escalation strategy for axillary management in breast cancer has been a consistent research focus in breast surgery. Last year, the SOUND study explored whether certain low-risk patients undergoing breast-conserving surgery could avoid sentinel lymph node biopsy (SLNB). At the 2024 San Antonio Breast Cancer Symposium (SABCS), the INSEMA study, a similar investigation, was presented. Oncology Frontier invited Dr. Yiding Chen from The Second Affiliated Hospital of Zhejiang University School of Medicine to provide an in-depth analysis of the INSEMA study.

The "2024 Yixian Breast Cancer Conference and the Second China Young Breast Cancer Consensus Conference" took place in Guangzhou from December 27 to 28, 2024. The conference explored cutting-edge topics such as the evolving epidemiology of young breast cancer, screening strategies, the impact of genetic mutations, treatment, and recovery approaches. Highlights included the release of the YBCC Consensus on Diagnosis and Treatment (Patient Edition), the China Genetic Mutation Pathogenicity Database, and the Young Breast Cancer Quality of Life Scale. Oncology Frontier interviewed Dr. Qiang Liu, the conference chair from Sun Yat-sen Memorial Hospital, Sun Yat-sen University, to discuss key highlights, the unique epidemiological characteristics of young breast cancer, and future plans for advancing standardized care in this area.

On December 28, 2024, the year-end meeting of the Youth Expert Committee of the Chinese Society of Clinical Oncology (CSCO) was successfully held in Shanghai. This event brought together renowned experts and promising young talents from across the country to explore new directions in cancer treatment. Oncology Frontier had the honor of interviewing Dr. Biyun Wang, Chair of the conference and a leading expert at Fudan University Shanghai Cancer Center, who shared key highlights of the conference, insights on the development of young oncologists, the achievements of CSCO YOUNG, and future plans.

As the year draws to a close, reflection and progress take center stage. The "2024 Beijing Forbidden City Annual Lung Cancer Conference and the 16th Multidisciplinary Seminar on Advances in Lung Cancer Diagnosis and Treatment," jointly organized by the Beijing Tumor Prevention and Research Association, the China Association of Senior Healthcare, the Beijing Medical Love Public Welfare Foundation, and the Beijing Chen Jumei Public Welfare Foundation, was successfully held on December 13–14, 2024, in Beijing.

Dr. Ming Zhao shares key insights on combining local and systemic therapies to improve liver cancer treatment outcomes. Learn how innovative approaches like immunotherapy and targeted treatments are transforming patient care.